Similar articles for PMID: 20571063

Year	Number of Results
1995	3
1996	1
1997	1
1998	1
1999	1
2000	1
2001	2
2002	4
2003	5
2004	3
2005	4
2006	6
2007	8
2008	5
2009	9
2010	7
2011	9
2012	7
2013	10
2014	4
2015	8
2016	11
2017	7
2018	6
2019	6
2020	6
2021	4
2022	1
2024	0

1

Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.

Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M. Kuroda J, et al. Mol Cancer Res. 2010 Jul;8(7):994-1001. doi: 10.1158/1541-7786.MCR-10-0040. Epub 2010 Jun 22. Mol Cancer Res. 2010. PMID: 20571063

2

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Shi X, et al. Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240172

3

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.

Rahmani M, Nguyen TK, Dent P, Grant S. Rahmani M, et al. Mol Pharmacol. 2007 Sep;72(3):788-95. doi: 10.1124/mol.106.033308. Epub 2007 Jun 26. Mol Pharmacol. 2007. PMID: 17595328

4

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.

Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Kuroda J, et al. Cell Death Differ. 2007 Sep;14(9):1667-77. doi: 10.1038/sj.cdd.4402168. Epub 2007 May 18. Cell Death Differ. 2007. PMID: 17510658

5

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Huang M, et al. Oncogene. 2002 Dec 12;21(57):8804-16. doi: 10.1038/sj.onc.1206028. Oncogene. 2002. PMID: 12483533

6

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.

Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Scappini B, et al. Cancer. 2004 Apr 1;100(7):1459-71. doi: 10.1002/cncr.20131. Cancer. 2004. PMID: 15042680 Free article.

7

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Kurosu T, et al. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14. Cancer Res. 2009. PMID: 19366808

8

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. Kuroda J, et al. Br J Haematol. 2008 Jan;140(2):181-90. doi: 10.1111/j.1365-2141.2007.06899.x. Epub 2007 Nov 20. Br J Haematol. 2008. PMID: 18028486 Free article.

9

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

Chen R, Gandhi V, Plunkett W. Chen R, et al. Cancer Res. 2006 Nov 15;66(22):10959-66. doi: 10.1158/0008-5472.CAN-06-1216. Cancer Res. 2006. PMID: 17108134

10

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T. Koch A, et al. Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21. Oncogene. 2008. PMID: 18427551

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

125 results

Results by year